Asian Growth Companies With High Insider Ownership In July 2026
Amidst a backdrop of geopolitical tensions and rising oil prices, Asian markets have shown resilience, with some indices advancing despite global uncertainties. In this environment, growth companies with high insider ownership can offer unique insights into potential long-term value, as insiders often align their interests closely with shareholders.
Top 10 Growth Companies With High Insider Ownership In Asia
| Name | Insider Ownership | Earnings Growth |
| Zhejiang Taotao Vehicles (SZSE:301345) | 27.9% | 31.5% |
| Suzhou Dongshan Precision Manufacturing (SZSE:002384) | 33.5% | 73.1% |
| Shanghai Biren Technology (SEHK:6082) | 11% | 116.9% |
| Seojin SystemLtd (KOSDAQ:A178320) | 22% | 110.6% |
| SEERS (KOSDAQ:A458870) | 33.2% | 41.5% |
| Meitu (SEHK:1357) | 22.8% | 31.3% |
| L&C BIOLTD (KOSDAQ:A290650) | 24% | 148.5% |
| Jiangxi Fushine Pharmaceutical (SZSE:300497) | 21.1% | 55.9% |
| Guangzhou Tinci Materials Technology (SZSE:002709) | 38.4% | 28.9% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 14.1% | 40.4% |
Let's uncover some gems from our specialized screener.
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)
Simply Wall St Growth Rating: ★★★★★★
Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of novel antibody-based drugs and pre-clinical research services across China, the United States, and internationally, with a market cap of approximately HK$60.16 billion.
Operations: Biocytogen Pharmaceuticals generates revenue through its research and development of novel antibody-based drugs and pre-clinical research services in China, the United States, and internationally.
Insider Ownership: 14.1%
Revenue Growth Forecast: 22.4% p.a.
Biocytogen Pharmaceuticals (Beijing) is experiencing significant growth, with earnings forecasted to rise 40.43% annually, outpacing the Hong Kong market. Despite a volatile share price recently, the company trades at 43.8% below estimated fair value and has no recent insider trading activity. A favorable legal judgment supports its innovative RenNano platform, while a collaboration with Whitehawk Therapeutics could enhance its bispecific antibody-drug conjugate pipeline. The addition to the S&P Global BMI Index underscores Biocytogen's growing prominence in biotechnology.
- Get an in-depth perspective on Biocytogen Pharmaceuticals (Beijing)'s performance by reading our analyst estimates report here.
- Insights from our recent valuation report point to the potential overvaluation of Biocytogen Pharmaceuticals (Beijing) shares in the market.
SENASIC Electronics Technology (SEHK:6675)
Simply Wall St Growth Rating: ★★★★★☆
Overview: SENASIC Electronics Technology Co., Ltd. focuses on the design, research and development, and sales of chip products in China, with a market cap of HK$9.08 billion.
Operations: SENASIC Electronics Technology Co., Ltd. generates revenue primarily from the sales of chip products, amounting to CN¥477.86 million.
Insider Ownership: 15.9%
Revenue Growth Forecast: 32.4% p.a.
SENASIC Electronics Technology recently completed a HK$980.55 million IPO, indicating strong market interest despite its illiquid shares. Revenue grew 37.5% last year and is forecasted to continue at 32.4% annually, surpassing the Hong Kong market average of 8.7%. Although currently unprofitable with a net loss of CNY 329.82 million in 2025, it is expected to achieve profitability within three years, driven by substantial revenue growth projections and insider ownership stability.
- Dive into the specifics of SENASIC Electronics Technology here with our thorough growth forecast report.
- Upon reviewing our latest valuation report, SENASIC Electronics Technology's share price might be too optimistic.
Rakus (TSE:3923)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Rakus Co., Ltd., along with its subsidiaries, offers cloud services in Japan and has a market capitalization of ¥375.36 billion.
Operations: The company generates revenue primarily from its Cloud Business, which accounts for ¥51.77 billion, and its IT Human Resources Business, contributing ¥8.53 billion.
Insider Ownership: 28.7%
Revenue Growth Forecast: 10.2% p.a.
Rakus is experiencing steady growth, with earnings projected to increase by 11.75% annually, outpacing the Japanese market average. Despite high share price volatility recently, it trades at a significant discount to its estimated fair value. Recent developments include a potential acquisition of Plus Alpha Consulting and an alliance agreement, which may enhance strategic capabilities. Sales for June 2026 slightly decreased compared to last year, but overall revenue growth remains positive above market averages.
- Delve into the full analysis future growth report here for a deeper understanding of Rakus.
- Our valuation report unveils the possibility Rakus' shares may be trading at a discount.
Summing It All Up
- Unlock our comprehensive list of 464 Fast Growing Asian Companies With High Insider Ownership by clicking here.
- Seeking Other Investments? Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com